Sinclair IS Pharma shares drop despite strong end to the year
Shares in Sinclair IS Pharma moved lower after the company reported a strong second half.
FTSE AIM 100
3,641.02
10:35 25/04/24
FTSE AIM All-Share
755.18
10:35 25/04/24
Pharmaceuticals & Biotechnology
22,658.74
10:35 25/04/24
Sinclair Pharma
31.80p
16:49 05/11/18
Sinclair IS Pharma shares were down by 2.19% to 44.75p at 16:18 BST.
The cosmetic treatment provider, which is in talks to be fully or partially sold, said like-for-like growth for the year was 8%, compared with 4% the year before.
Sinclair said this growth showed the impact of its aesthetics portfolio, which made up 47% of reported revenue, at £35.8m.
Full year revenues were up by 19% to £75.9m, compared to £63.6m last year.
Sinclair ended the year with cash of £12.7m and net debt of £42.2m.
Chief executive Chris Spooner said the second half had made up for a disappointing first half which was poorer due to delays and teething problems with new products.